Loading...

Fuse Medical

OTCPK:FZMD
Snowflake Description

Mediocre balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FZMD
OTCPK
$35M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Fuse Medical, Inc. distributes medical devices in the United States. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Fuse Medical has significant price volatility in the past 3 months.
FZMD Share Price and Events
7 Day Returns
66.7%
OTCPK:FZMD
0.1%
US Healthcare
0.5%
US Market
1 Year Returns
-50.5%
OTCPK:FZMD
-3.8%
US Healthcare
0.8%
US Market
FZMD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Fuse Medical (FZMD) 66.7% 66.7% - -50.5% - -
US Healthcare 0.1% 3.5% -1.8% -3.8% 23% 61.2%
US Market 0.5% -0.1% 1% 0.8% 37.5% 37.5%
1 Year Return vs Industry and Market
  • FZMD underperformed the Healthcare industry which returned -3.8% over the past year.
  • FZMD underperformed the Market in United States of America which returned 0.8% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

FZMD Value

 Is Fuse Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Fuse Medical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Fuse Medical.

OTCPK:FZMD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:FZMD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.638 (1 + (1- 21%) (4.41%))
0.772
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for OTCPK:FZMD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Fuse Medical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:FZMD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.5%)
2019 1.63 Est @ -10.95% 1.52
2020 1.52 Est @ -6.85% 1.32
2021 1.46 Est @ -3.97% 1.18
2022 1.43 Est @ -1.96% 1.07
2023 1.42 Est @ -0.55% 0.99
2024 1.43 Est @ 0.43% 0.93
2025 1.45 Est @ 1.12% 0.87
2026 1.47 Est @ 1.6% 0.82
2027 1.50 Est @ 1.94% 0.78
2028 1.53 Est @ 2.18% 0.74
Present value of next 10 years cash flows $10.22
OTCPK:FZMD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1.53 × (1 + 2.73%) ÷ (7.5% – 2.73%)
$32.97
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $32.97 ÷ (1 + 7.5%)10
$16.00
OTCPK:FZMD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $10.22 + $16.00
$26.22
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $26.22 / 70.22
$0.37
OTCPK:FZMD Discount to Share Price
Calculation Result
Value per share (USD) From above. $0.37
Current discount Discount to share price of $0.50
= -1 x ($0.50 - $0.37) / $0.37
-33.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Fuse Medical is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Fuse Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Fuse Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:FZMD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.06
OTCPK:FZMD Share Price ** OTCPK (2019-06-11) in USD $0.5
United States of America Healthcare Industry PE Ratio Median Figure of 57 Publicly-Listed Healthcare Companies 22.53x
United States of America Market PE Ratio Median Figure of 3,094 Publicly-Listed Companies 17.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Fuse Medical.

OTCPK:FZMD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:FZMD Share Price ÷ EPS (both in USD)

= 0.5 ÷ 0.06

8.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fuse Medical is good value based on earnings compared to the US Healthcare industry average.
  • Fuse Medical is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Fuse Medical's expected growth come at a high price?
Raw Data
OTCPK:FZMD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 8.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Healthcare Industry PEG Ratio Median Figure of 43 Publicly-Listed Healthcare Companies 1.68x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Fuse Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Fuse Medical's assets?
Raw Data
OTCPK:FZMD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.02
OTCPK:FZMD Share Price * OTCPK (2019-06-11) in USD $0.5
United States of America Healthcare Industry PB Ratio Median Figure of 93 Publicly-Listed Healthcare Companies 2.31x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
OTCPK:FZMD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:FZMD Share Price ÷ Book Value per Share (both in USD)

= 0.5 ÷ 0.02

29.26x

* Primary Listing of Fuse Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fuse Medical is overvalued based on assets compared to the US Healthcare industry average.
X
Value checks
We assess Fuse Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Fuse Medical has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

FZMD Future Performance

 How is Fuse Medical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Fuse Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.2%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Fuse Medical expected to grow at an attractive rate?
  • Unable to compare Fuse Medical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Fuse Medical's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Fuse Medical's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:FZMD Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:FZMD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:FZMD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 25 2 4
2018-12-31 26 2 4
2018-09-30 26 3 -2
2018-06-30 25 2 -2
2018-03-31 27 2 0
2017-12-31 26 2 1
2016-12-31 26 3 3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Fuse Medical is high growth as no earnings estimate data is available.
  • Unable to determine if Fuse Medical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:FZMD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Fuse Medical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:FZMD Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.06
2018-12-31 0.06
2018-09-30 -0.03
2018-06-30 -0.03
2018-03-31 0.01
2017-12-31 0.04
2016-12-31 0.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Fuse Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of FZMD’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Fuse Medical's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Fuse Medical's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Fuse Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Fuse Medical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

FZMD Past Performance

  How has Fuse Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Fuse Medical's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient data to establish if Fuse Medical's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Fuse Medical's 1-year earnings growth to the 5-year average due to insufficient past data.
  • Fuse Medical's earnings growth has exceeded the US Healthcare industry average in the past year (753.9% vs 2.2%).
Earnings and Revenue History
Fuse Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Fuse Medical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:FZMD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 25.11 4.18 14.49
2018-12-31 26.34 3.96 14.90
2018-09-30 26.01 -1.97 14.61
2018-06-30 25.24 -1.74 13.46
2018-03-31 26.82 0.49 11.67
2017-12-31 26.41 0.70 10.96
2016-12-31 25.67 3.02 11.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst Fuse Medical made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.
  • Fuse Medical used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.
  • It is difficult to establish if Fuse Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Fuse Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Fuse Medical has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

FZMD Health

 How is Fuse Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Fuse Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Fuse Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Fuse Medical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Fuse Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 9.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Fuse Medical Company Filings, last reported 2 months ago.

OTCPK:FZMD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 1.20 1.55 0.85
2018-12-31 1.47 1.63 0.84
2018-09-30 -5.01 0.91 0.59
2018-06-30 -8.80 2.17 0.69
2018-03-31 -8.58 2.82 0.80
2017-12-31 -7.98 3.57 0.80
2016-12-31 10.60 3.46 0.78
  • Fuse Medical's level of debt (128.9%) compared to net worth is high (greater than 40%).
  • Unable to establish if Fuse Medical's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (118.5%, greater than 20% of total debt).
  • Unable to confirm if the interest payments on Fuse Medical's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Fuse Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Fuse Medical has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

FZMD Dividends

 What is Fuse Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Fuse Medical dividends.
If you bought $2,000 of Fuse Medical shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Fuse Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Fuse Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:FZMD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 1.6%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Fuse Medical has not reported any payouts.
  • Unable to verify if Fuse Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Fuse Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Fuse Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Fuse Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Fuse Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Fuse Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

FZMD Management

 What is the CEO of Fuse Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Reeg
COMPENSATION $453,050
AGE 54
TENURE AS CEO 2.5 years
CEO Bio

Mr. Christopher C. Reeg, also known as Chris, has been Chief Executive Officer and Director of Fuse Medical, Inc. since December 19, 2016 and is its Secretary since January 18, 2018. He serves as the President of Reeg Medical Industries, Inc. Mr. Reeg was Chief Executive Officer and Director of Fuse Medical, Inc., Prior to Reverse Merger with CPM Medical Consultants, LLC since December 19, 2016. Mr. Reeg is the Founder of Maxim Surgical and serves as its President.

CEO Compensation
  • Chris's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Chris's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Fuse Medical management team in years:

2.2
Average Tenure
54
Average Age
  • The tenure for the Fuse Medical management team is about average.
Management Team

Mark Brooks

TITLE
Chairman of the Board & President
COMPENSATION
$1M
AGE
52
TENURE
1.4 yrs

Chris Reeg

TITLE
CEO, Secretary & Director
COMPENSATION
$453K
AGE
54
TENURE
2.5 yrs

William McLaughlin

TITLE
CFO, Treasurer & Director
COMPENSATION
$300K
AGE
54
TENURE
2.2 yrs
Board of Directors Tenure

Average tenure and age of the Fuse Medical board of directors in years:

2.5
Average Tenure
53
Average Age
  • The average tenure for the Fuse Medical board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mark Brooks

TITLE
Chairman of the Board & President
COMPENSATION
$1M
AGE
52
TENURE
2.5 yrs

Chris Reeg

TITLE
CEO, Secretary & Director
COMPENSATION
$453K
AGE
54
TENURE
2.5 yrs

William McLaughlin

TITLE
CFO, Treasurer & Director
COMPENSATION
$300K
AGE
54
TENURE
2.5 yrs

Ricky Kalra

TITLE
Independent Director
COMPENSATION
$105K
AGE
36
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
27. Nov 18 Buy Reeg Medical Industries, Inc. Company 04. Oct 18 04. Oct 18 72,139 $0.68 $49,055
27. Nov 18 Buy Reeg Medical Industries, Inc. Company 01. Aug 18 01. Aug 18 2,539,474 $0.76 $1,930,000
X
Management checks
We assess Fuse Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Fuse Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

FZMD News

Simply Wall St News

FZMD Company Info

Description

Fuse Medical, Inc. distributes medical devices in the United States. The company offers orthopedic implants, including internal and external fixation products; upper and lower extremity plating and total joint reconstruction implants; soft tissue fixation and augmentation for sports medicine procedures; full spinal implants for trauma, degenerative disc disease, and deformity indications; and various osteo-biologics, and regenerative and amniotic tissues, which comprise human allografts, substitute bone materials, tendons, and regenerative tissues and fluids. It also manufactures medical devices for the orthopedic and spine markets. The company serves hospitals, medical facilities, and sub-distributors. Fuse Medical, Inc. is based in Richardson, Texas.

Details
Name: Fuse Medical, Inc.
FZMD
Exchange: OTCPK
Founded:
$35,110,783
70,221,566
Website: http://www.fusemedical.com
Address: Fuse Medical, Inc.
1565 North Central Expressway,
Suite 200,
Richardson,
Texas, 75080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK FZMD Common Stock Pink Sheets LLC US USD 02. Jan 2018
Number of employees
Current staff
Staff numbers
0
Fuse Medical employees.
Industry
Health Care Distributors
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/17 01:23
End of day share price update: 2019/06/11 00:00
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.